In-licensing of NS-917 (DFP-10917)
First written in FY2017. 21 of 24 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and has been undergoing a Phase 1 trial since February 2022.」
NS-917 continues to undergo the Phase 1 trial that began in February 2022 following its in-licensing. - FY2024-Q3RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and has been undergoing a Phase 1 trial since February 2022.」
NS-917 continues to undergo the Phase 1 trial that began in February 2022 following its in-licensing. - FY2024-Q2RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and has been undergoing a Phase 1 trial since February 2022.」
NS-917 continues to undergo the Phase 1 trial that began in February 2022 following its in-licensing. - FY2024-Q1RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and has been undergoing a Phase 1 trial since February 2022.」
NS-917 continues to undergo the Phase 1 trial that began in February 2022 following its in-licensing. - FY2023RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and has been undergoing a Phase 1 trial since February 2022.」
NS-917 continues to undergo the Phase 1 trial that began in February 2022 following its in-licensing. - FY2023-Q2RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and has been undergoing a Phase 1 trial since February 2022.」
The company restated that, following its in-licensing, NS-917 has been undergoing a Phase 1 trial that began in February 2022. - FY2023-Q1AdvancedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and has been undergoing a Phase 1 trial since February 2022.」
NS-917 progressed from the Phase 1 trial preparation stage to the Phase 1 trial stage in February 2022. - FY2022-Q3RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and is currently in preparation for a Phase 1 trial.」
The company restated that NS-917 is in preparation for a Phase 1 trial following its in-licensing. - FY2022-Q2RestatedAnnual report
「The treatment NS-917 (generic name: radgocitabine) for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and is currently in preparation for a Phase 1 trial.」
The company restated that NS-917 is in preparation for a Phase 1 trial following its in-licensing. - FY2022-Q1RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and is currently in preparation for a Phase 1 trial.」
The company restated that NS-917 is in preparation for a Phase 1 trial following its in-licensing. - FY2021RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and is currently in preparation for a Phase 1 trial.」
The company restated that NS-917 is in preparation for a Phase 1 trial following its in-licensing. - FY2021-Q3AdvancedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and is currently in preparation for a Phase 1 trial.」
The description of NS-917 was made more specific, changing from being in development preparation to being in preparation for a Phase 1 trial. - FY2021-Q2RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2021-Q1RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2020-Q3RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2020-Q2RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2020-Q1RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2019-Q3RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2019-Q2RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March of the previous year and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2019-Q1RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March of the previous year and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2018-Q3RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2018-Q2RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2018-Q1RestatedAnnual report
「The treatment NS-917 for relapsed or refractory acute myeloid leukemia was in-licensed from デルタフライファーマ株式会社 (Tokushima) in March 2017 and is currently in development preparation.」
The company restated that NS-917 remains in the development preparation stage following its in-licensing. - FY2017First statedAnnual report
「In March 2017, the company in-licensed the treatment NS-917 for relapsed or refractory acute myeloid leukemia from デルタフライファーマ株式会社 (Tokushima).」
The company in-licensed a treatment for relapsed or refractory acute myeloid leukemia from デルタフライファーマ株式会社.